Stocks opened the week with a strong performance yesterday. All three major U.S. indices posted 1.0%+ gains. The tech-heavy Nasdaq led the day with a 1.8% advance.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Early-morning futures action is currently pointing to a higher open S&P 500 futures are currently up 0.7% and Nasdaq futures are up 0.9% as tech stocks look to recapture their recent losses.
Traders are expecting a positive Industrial Production report today with an increase in industrial production, led by an jump in manufacturing output. However, the numbers will be closely scrutinized, and the market could turn sour if it doesn’t get what it wants.
Asian stocks were mixed overnight. Japan’s Nikkei 225 lost 0.4% and China’s Shanghai Composite gained 0.5%. In Europe, most major indices are in the green, and the British FTSE 100 is leading the way with a 1.1% gain. The Eurozone Stoxx 600 is also up 0.7%.
Today’s featured earnings docket includes a pre-bell report from Cracker Barrel [CBRL]. After the session closes, we’ll hear from FedEx [FDX] and Adobe [ADBE].
Here’s what’s moving the market this morning:
NextEra Energy (NEE)
NextEra is running hot today after its board approved a 4-for-1 stock split. Holders of NEE will receive three additional shares for every one they hold. The split is scheduled to go into effect on October 26.
The company also raised its earnings forecast for 2021 and 2022 and extended its longer-term growth forecast to 2023. NextEra said its increasing its financial expectations to by $0.20 per share, which brings its annual forecast to between $9.60 and $10.15. Consensus estimates are currently at $9.88.
NextEra is rallying on the news. It’s one of the most active S&P 500 stocks and its 7.1% after-hours gain is currently leading the index.
LG DIsplay Co (LPL)
LG Display lost a prominent Chinese customer due to U.S. restrictions. Last Tuesday, the company announced it would stop supplying display panels to China’s Huawei Technologies [HWT.UL] because of U.S. sanctions against the company. The company said it expects the move will have minimal impact because it only made limited panel shipments to Huawei and promised to expand its customer base. However, the decision to drop Huawei could hurt their standing in the Chinese market.
LPL performed well after the news broke and closed last week with gains. However, it’s losing some steam today. LPL is down 12.5% in the pre-market.
Novus Therapeutics (NVUS)
Novus Therapeutics has successfully closed on its Anelixis Therapeutics acquisition and secured a round of private placement financing. The stock-for-stock transaction included an exchange of all of Anelixis outstanding shares in return for Novus common stock and preferred stock.
The company also completed its private placement funding round with $108 million in proceeds. Novus says it will use the money to “advance AT1501 Phase 2 Clinical trials in up to four indications. AT1501 is an experimental anti-CD40L antibody that could be useful in therapy for organ and cellular transplantaion, autoimmune diseases, and neurodegenerative diseases.
Plus Therapeutics (PSTV)
This micro-cap biotech firm landed a pivotal approval from the U.S. Food and Drug Administration. The FDA awarded Plus Therapeutics with a “Fast Track” designation for its novel glioblastoma treatment. Fast Tracked drugs get better access to FDA regulators and eligibility for Accelerated Approval and Priority Review.
CEO Dr. Marc Hedrick: “Fast Track designation validates the potential importance of this novel radiotherapeutic for patients with recurrent glioblastoma who currently have no good treatment options… With this designation in hand, we intend to move into Cohort 6 of the trial, one key step closer to bringing forth a novel therapy for these patients.”
PSTV is trading actively in the pre-market and it’s currently up 55.7%.